A month has gone by since the last earnings report for Pfizer (PFE). Shares have lost about 1.9% in that time frame, outperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release,

There is no better period, given the volatility in the markets today, to rotate assets into dividend stocks, said Steven Cress, VP of Quantitative Strategy at Seeking Alpha. During Seeking Alpha’s Dividend Investing Forum virtual event,

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. It's no secret why Pfizer has not performed well recently. The company was never going to keep up those sales year in and year out.

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy rating on PFE stock.

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing 530% to $0.63. Explore more details here.

Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous

Says “I don’t think the Street” has adjusted yet and that “they should have a look on it.” The company says the rebates that Pfizer (PFE) will

Uniondale-based McHugh Furnishings, a provider of specialty furnishings for education, healthcare, entertainment and multifamily housing, has expanded with the acquisition of an upstate furniture company.

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE),

A German court ruled that BioNTech (BNTX) and Pfizer (PFE) have to pay Moderna damages because they infringed on Moderna

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned +0.

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...